Search

Search Constraints

You searched for: Author/Creator Vidal, V.

Search Results

2. 50 BCL2L10-POSITIVE CELL (BPC) QUANTIFICATION IS A PREDICTIVE FACTOR OF SURVIVAL IN AZA-TREATED HIGHER RISK MDS (HR-MDS) AND AML. (April 2015)

7. Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia. Issue 7 (7th June 2021)

8. Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Issue 2 (28th January 2021)

9. Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Issue 2 (28th January 2021)